Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women.
Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.
Unadkat
Jashvant D
JD
Department of Pharmaceutics, University of Washington, Box 357610, Seattle, WA 98195, USA. jash@u.washington.edu
Wara
Diane W
DW
Hughes
Michael D
MD
Mathias
Anita A
AA
Holland
Diane T
DT
Paul
Mary E
ME
Connor
James
J
Huang
Sharon
S
Nguyen
Bach-Yen
BY
Watts
D Heather
DH
Mofenson
Lynne M
LM
Smith
Elizabeth
E
Deutsch
Paul
P
Kaiser
Kathleen A
KA
Tuomala
Ruth E
RE
D000328:Adult; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000009:adverse effects / Q000493:pharmacokinetics; D007231:Infant, Newborn; D008099:Liver / Q000378:metabolism; D008297:Male; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*
D017320:HIV Protease Inhibitors; D019469:Indinavir; D051544:Cytochrome P-450 CYP3A